Use of the Functional Assessment of Cancer Therapy−Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia-Reference-Cited by-同舟云学术

Use of the Functional Assessment of Cancer Therapy−Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

Published:2014-04 Issue:4 Volume:36 Page:560-566
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Tefferi Ayalew,Hudgens Stacie,Mesa Ruben,Peter Gale Robert,Verstovsek Srdan,Passamonti Francesco,Cervantes Francisco,Rivera Candido,Tencer Tom,Khan Zeba M.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference16 articles.

1. The forgotten myeloproliferative disorder: myeloid metaplasia;Tefferi;Oncologist,2003

2. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients;Mesa;Cancer,2007

3. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial;Mesa;Cancer,2011

4. Health-related quality of life and productivity impact of myelodysplastic syndrome (MDS): the patient perspective;Komrokji;12th International Symposium on Myelodysplastic Syndromes,2013

5. Guideline for the diagnosis and management of myelofibrosis;Reilly;Br J Haematol,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis;Blood Advances;2024-08-28

2. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients;Annals of Hematology;2024-07-29

3. Effect of Hemoglobin on the Prognosis of Patients With Advanced Cancer in Palliative Care Settings;Palliative Medicine Reports;2024-05-01

5. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial;Leukemia & Lymphoma;2024-03-19